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Abstract
Prostate cancer is the second leading cause of cancer-related deaths in men. Activation of MAP kinase signaling pathway
has been implicated in advanced and androgen-independent prostate cancers, although formal genetic proof has been
lacking. In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a
genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAF
V600E–a
mutation found in ,10% of human prostate tumors–was targeted to the epithelial compartment of the prostate gland on
the background of Ink4a/Arf deficiency. These GEM mice developed prostate gland hyperplasia with progression to rapidly
growing invasive adenocarcinoma without evidence of AKT activation, providing genetic proof that activation of MAP
kinase signaling is sufficient to drive prostate tumorigenesis. Importantly, genetic extinction of BRAF
V600E in established
prostate tumors did not lead to tumor regression, indicating that while sufficient to initiate development of invasive
prostate adenocarcinoma, BRAF
V600E is not required for its maintenance.
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Introduction
Prostate cancer (PCA) is the most common malignancy affecting
men over age of 65. Initially responsive to hormonal ablation
therapy, PCA invariably recur and evolve to become lethal
androgen-independent (AI) disease. While a number of common
genetic events have been implicated in human prostate carcino-
genesis including those targeting PTEN, RB, and p27 tumor
suppressors, NKX3.1 tumor modulator, and the c-Myc onco-
gene[1,2,3,4,5], the genetic and biological basis governing
progression to invasive and metastatic or AI disease is less well
understood. Extensive genetic and experimental evidence have
underscored the importance of the PI3K-PTEN-AKT signaling
pathway, not only in genesis[3,4,5] but also in progression[6,7] of
PCA. In addition, specific genetic events, such as androgen
receptor mutation or amplification, Bcl2 activation, and/or loss of
p53 tumor suppressor function, had been associated with
transition to AI disease[5,8,9,10,11,12,13,14,15,16].
In contrast, the role of activated RAS-RAF-MAPK signaling in
PCA is less well-established, although a growing body of evidence
implicates the pathogenetic relevance of this pathway in prostate
cancer biology. First, MAP kinase activation has been shown to
correlate with disease progression in human PCA specimens[17].
Second, virtually all AI xenografts exhibit elevated phospho-MAP
kinase levels and RAS activation renders LNCaP cells less
dependent on androgens in vitro[18]. Furthermore, analysis of
various RAS effecter mutants with differential capacity to engage
specific downstream signaling pathways has also highlighted the
MAPK axis in reducing androgen-dependence of LNCaP cells.
Third, activating mutations in all three RAS family members have
been reported in human PCA specimens[19], primarily from
Japanese men, wherein these early studies reported a 13–30%
frequency of mutations[20,21,22,23,24]. More recently, in a study
of Korean patients, KRAS activating mutations were detected in
7% of cases and another 10% harbored the BRAF
V600E activating
mutation[25]. In consonance with these mutation data, Raf1
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3949expression is often found to be elevated and B-Raf inhibitor
reduced in human prostate tumors[26]. Lastly, ETV1/ER85, a
partner in the high frequency TMPRSS2:ETV1 chromosomal
fusion event in human prostate cancer, is a downstream target of
RAS-RAF-MAPK signaling[27]. These reinforcing, albeit correl-
ative, data have implicated activated RAS-RAF-MAPK signaling
in the prostate cancer genesis and progression.
Genetically engineered mouse (GEM) models have enabled the
validation and functional analysis of several key genetic alterations
found in prostate cancer development (reviewed in[28,29]. The
majority of invasive PCA GEM models have largely emphasized
AKT activation strategies such as myr-AKT or Pten deletion, alone
or together with p53 or p27 inactivation[3,4,5,12,30,31,32]. Other
well-established models include prostate-specific expression of c-
Myc or SV40 oncogenes[1,33,34]. GEM model of invasive prostate
cancers driven by MAPK activation has not been reported.
Previously, we have engineered an inducible bitransgenic
HRAS
V12-driven melanoma model possessing both activator
(Tyr-rtTA) and reporter (Tet-HRAS
V12) transgenes on Ink4a/
Arf2/2 background (hereafter designated as ‘‘iHRAS*’’)[35]. The
rtTA transgene was driven by a Tyrosinase enhancer-promoter
element consisting of a 5 Kb upstream enhancer element fused to
the proximal promoter of mouse tyrosinase gene[36]. This
promoter has been used extensively as a melanocyte-specific
promoter element[35,36,37]. To our surprise, while majority of
the iHRAS* mice succumbed to invasive and angiogenic
cutaneous melanomas in a doxycycline-dependent manner[35],
a handful of the aging male mice that escaped the melanoma fate
developed invasive prostate tumors (unpublished observations).
Similarly, male mice from an identically engineered iNRAS*
model also succumbed to prostate cancer if they did not develop
melanoma (unpublished observations). These unanticipated ob-
servations suggest that prostate cancer is a late-onset tumor
phenotype in RAS-activated GEM models engineered with this
particular tyrosinase promoter-enhancer element. Furthermore, it
raised the possibility that oncogenic alleles with weaker activity in
melanocytes might favor more robust prostate cancer phenotype.
Indeed, when we constructed an iBRAF* model, the iBRAF*
mice were minimally melanoma-prone (data not shown). Instead
the iBRAF* transgenic males were highly susceptible to the
development of aggressive prostate neoplasms in a doxycycline-
dependent manner. Since activated BRAF is one of the most
potent activators of MAP kinase signaling and BRAF
V600E
mutation itself has been described in a subset of human prostate
cancers[25], this iBRAF* model represents a potentially useful in
vivo system in which to address the role of MAP kinase activation
in prostate cancer genesis and progression.
Results
BRAF* activation drives aberrant proliferation in p63+
basal epithelial cells of the prostate
The occurrence of prostate cancers in tyrosinase promoter/
enhancer-driven transgenic mice prompted a detailed analysis of
transgene expression in the prostate. Examination of transgene
expression was performed in all 3 lobes of the prostate glands in 8-
week-old bi-transgenic iBRAF* males (iBRAF*, short for ‘‘Tyr-
rtTA::Tet-BRAF
*::Ink4a/Arf2/2’’). We detected BRAF* transcripts
in all 3 lobes of iBRAF* mice on doxycycline (n=2 mice examined),
but not in whole prostate glands derived from WT or iBRAF*
transgenic males off doxycycline using transgene-specific RT-PCR
(Figure 1A; n=2 for each). As RNA in situ hybridization (RISH) of
BRAF detects both endogenous BRAF and transgene BRAF*
expression throughout the prostatic epithelium (data not shown),
we tracked transgene BRAF* expression by rtTA RISH (nb., rtTA is
foreign to the mammalian genome). Upon doxycycline exposure,
rtTA is known to potently drive expression of a transgene linked to a
Tet-responsive promoter and is therefore a highly specific read-out
of the Tet-driven transgene (BRAF* in this case) expression. rtTA
transcripts were not detected in non-transgenic wild-type prostate
gland, yet were abundant in iBRAF* transgenic prostates exposed to
doxycycline (Figure 1B), particularly in the luminal cells (Figure 1B,
zoom-in panel, see arrows). To further refine localization of
transgene expression in the epithelium and determine whether the
transgene is also expressed in the basal cell compartment, we
performed serialp63IHCand rtTARISH(see Materials& Methods)
in 8-week-old male iBRAF* prostate glands induced on doxycycline
(Figure 1C). Indeed, rtTA transcripts were found in both p63+ basal
cells and luminal cells (approximately 50% of the p63+ basal cells
showed stronger rtTA expression; see arrows), indicating that this
transgenic system can target expression to both the basal progenitor
and the luminal compartments of prostate glands.
To examine the functional impact of BRAF* transgene
expression in the prostate, we monitored doxycycline-dependent
proliferative responses in histologically normal prostates of
iBRAF* and control mice. These analyses revealed enhanced
epithelial proliferation documented by increased Ki67 index from
2.25 (+/20.83) per 100 nuclei in 8-week-old WT to 6.9 (+/20.95)
per 100 nuclei in age-matched iBRAF* prostate (n=300 nuclei/
area65 areas counted in each sample; p=0.00035; Figure 1D).
Notably, this BRAF*-induced proliferative response was more
prominent in the basal cell compartment, as evident by the
observation that most of the strong Ki67 positive signals were
confined to p63+ cells (Figure 1E; approximately 50% of p63+
basal cells in iBRAF* prostate glands were positive for Ki67).
iBRAF* mice developed invasive adenocarcinoma of the
prostate
A serial histopathological examination of the prostates from
iBRAF* transgenic males was conducted to assess the long-term
consequences of sustained BRAF* expression in the prostate
epithelium. After 5 weeks of iBRAF* induction in 8-week-old
animals (left panel in Figure 2A), the prostate gland appeared
largely normal although moderate degree of aberrant proliferation
was already evident (Figure 1E). Basaloid hyperplasia became
evident in 16-week-old mice (middle panel in Figure 2A), consistent
with prominent proliferative responses in the basal compartment
(Figure 1E), followed by emergency of frank adenocarcinoma by 24
weeks of age (right panel in Figure 2A). Careful follow-up and
characterization of a large colony of iBRAF* and control mice
showed that only iBRAF* males on doxycycline were prone to PCA
development with high penetrance. In founder line #29, 21/34 bi-
transgenic iBRAF* males on doxycycline (ON) developed prostate
tumors with an average latency of 24 weeks (SD=66 weeks)
(Figure 2B, Supporting Table S1). In comparison, all iBRAF* mice
off doxycycline (OFF, n=10) and single transgenic Tet-BRAF*
mice (e.g. Tet-B-RAF*::Ink4a/Arf2/2) on doxycycline (ON, n=9)
remained PCA free (Supporting Table S1). Similar observations
were made in a smaller cohort derived from founder line #13
where 3/10 doxycyline-treated iBRAF* males developed PCA with
a latency of 2366 weeks (Supporting Table S1). Additionally,
BRAF* transgene expression could be documented in these PCA
tumors by RT-PCR and RISH (Supporting Figure S1; data not
shown for RISH).
iBRAF* PCA tumors were rapidly growing, reaching large size
and causing local obstruction (Figure 2C). Consistent with its
aggressive nature, iBRAF* tumors exhibited epithelial-mesenchy-
mal transition (EMT) associated with downregulation of E-
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PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e3949cadherin at the transition from ductal to spindle morphology in
these tumors (Figure 2D, compare asterisk to arrow). By high-
spatial resolution MRI, PCA could be readily discerned by the
appearance of an enlarged, heterogeneous mass often compressing
the bladder (Figure 2E-b, dashed outline; see panel E-a for normal
prostate size marked by blue highlight). As in some human
patients, these large lesions caused bladder outlet obstruction and
hydronephrosis–distention of the kidney due to outflow obstruc-
tion (Figure 2E-c yellow arrow).
The complex and context-specific interactions between RAS
and PI3K signaling components coupled with the well-document-
ed prominence of PI3K-PTEN-AKT aberrations in PCA
prompted analysis of downstream signaling events in a collection
of iBRAF* PCA tumors. Consistent with the known ability to
BRAF* to potently activate MAPK signaling, all iBRAF* tumors
showed p-ERK activation by Western blot and IHC analyses
(Figure 5A,B). Notably, while Western blot analysis of Pten-null
PCA showed strong AKT activation, none of the iBRAF* tumors
examined showed AKT activation (Figure 5A). IHC analysis of
additional iBRAF* prostate tumors (n=17) mirrored these
Western blot results, showing absence of AKT activation and
readily detectable p-S6 immunoreactivity (Figure 5C). Thus,
activated BRAF* expression targeted to prostate epithelium in
the context of Ink4a/Arf deficiency triggers a proliferative response
in the basal p63+ compartment, which when sustained, progresses
with high penetrance to basaloid hyperplasia and ultimately
invasive adenocarcinoma, without evidence for concomitant AKT
activation.
Figure 1. Transgene BRAF* expression in prostate epithelium drives aberrant proliferation of the p63+ prostatic basal cells. A.
Transgene BRAF* transcript was detected in all three lobes (AP, anterior prostate; VP, ventral prostate; DLP, dorsolateral prostate) of the prostate
glands from two independent 8-week-old bi-transgenic iBRAF* male mice on doxycycline by transgene-specific RT-PCR. As controls, whole prostate
glands were isolated from WT or iBRAF* off doxycycline mice (n=2 for each). Ribosomal protein R15 was used as an internal control for RT-PCR. B.
RNA in situ hybridization (RISH) using rtTA riboprobe documented expression of BRAF* transgene in prostate epithelial gland (2006). Arrows indicate
the expression of rtTA in luminal cell compartment in zoom-in with higher magnification (4006). C. Expression of BRAF* transgene was detected in
both luminal cells and p63+ basal cells of the prostate epithelium of 8-week-old bi-transgenic iBRAF* male mice on doxycycline using dual serial
staining of p63 IHC and rtTA RISH. After quick incubation of slides with antibody against p63 for 10 minutes with IHC procedure, RISH procedure with
rtTA RNA probe was followed. Brown color for p63+ basal cells by IHC and purple color for rtTA expression by RISH were differentially detected by
spectro-imaging machine. Note the co-localization of strong rtTA expression and p63 immuno-reactivity in approximately 50% of p63+ basal cells
(arrows). D. Ki67 staining of histologically-normal prostate glands in 8-week-old males showed increased proliferation index in iBRAF* transgenic (on
doxycycline) compared to WT. E. Co-immunofluorescence study in prostate glands isolated from 8-week-old WT and iBRAF* transgenic (on
doxycycline) males showed the expansion of p63+ basal cells in the prostate glands of iBRAF* mice. Approximately half of the p63+ cells were in
proliferation as measured by co-staining with Ki67 (see arrows).
doi:10.1371/journal.pone.0003949.g001
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Given the complex histopathological presentation of the tumors,
we utilized a suite of validated prostate lineage markers to
determine the origin of these iBRAF* tumors. As shown in
Figure 3, androgen receptor (AR) and Nkx3.1 are expressed in
both ductal and spindled components. Nkx3.1 is the earliest
known differentiation marker of the prostate luminal epitheli-
um[8], and interestingly its expression was significantly reduced or
absent in the spindled cell region of the tumors, possibly reflecting
a less differentiated state. Basal cell markers, cytokeratin (CK) 14
and p63 were strongly positive, especially in the ductal
components, as was CK19, a marker for transit-amplifying or
intermediate differentiated cell[38,39]. This epithelial markers
profile, coupled with negative immunoreactivity to chromogranin
and synaptophysin, two markers of neuroendocrine cells[40]
(Supporting Figure S2), indicates that iBRAF* PCA are epithelial
tumors.
To functionally document the epithelial nature of iBRAF* PCA,
we utilized the tissue recombinant approach pioneered by Cunha
and colleagues[41]. Here, recombinant of epithelium from iBRAF*
or wild type micewas mixed with mesenchymal tissues from miceor
rats (Figure 4A for design) then grafted under the kidney capsules of
adult nude male mice. Grafts were harvested 6 weeks later. As
shown in Figure 4B, Recomb A grafts (comprising iBRAF*
epithelium and rat mesenchyme) were significantly larger than
Recomb B grafts (the converse) from nude mice supplemented with
doxycycline drinking water (Figure 4B left panel). On the other
hand, without doxycycline, Recomb A grafts were normal in size
(Figure 4B right panel). Histological analysis of these grafts
confirmed basaloid hyperplasia and PIN in grafts from Recomb A
ON doxycycline only, while Recomb B grafts from the same hosts
or Recomb A from hosts without doxycycline showed normal
glandular structure that was indistinguishable from the Recomb C
and D controls (Figure 4C). These doxycyline-induced hyperplastic
and PIN lesions from Recomb A ON doxycycline grafts exhibited
similar marker profile as described for tumors from the de novo
transgenic mice-positive for Nkx3.1, AR, CK19, CK14 and p63
(Supporting Figure S3; data not shown for CK19 and CK14) as well
as evidence for significant expansion of the p63+ compartment
(Supporting Figure S3). On the biochemical level, a profile of robust
Figure 2. iBRAF* transgenic males develop invasive adenocar-
cinoma of the prostate. A. Time-course histological analysis of
prostate samples from iBRAF* transgenic mice (on doxycycline) at the
indicated ages. Hyperplastic lesions were detected in a 16-week-old
iBRAF* transgenic mouse on doxycycline. Up to an age of 24 weeks,
approximately 50% of iBRAF* transgenic mice developed PCA. B.
Kaplan-Meier analysis of PCA-free survival in iBRAF* (on doxycycline,
n=34), iBRAF* (off doxycycline, n=9), and Tet-BRAF* (on doxycycline,
n=10) transgenic males. Only double transgenic iBRAF* mice given
doxycycline in their drinking water developed PCA with an average
latency of 24 weeks (standard deviation=66 weeks). C. Gross
morphology of a prostate tumor from an iBRAF* transgenic mouse. T
indicates tumor; B, bladder; and Te, testis. D. The transition from ductal
(arrowhead) to spindle (asterisk) morphology is coincident with loss of
E-cadherin expression in iBRAF* PCA, consistent with EMT (epithelial-
mesenchymal transition). E. Detection of PCA in live mice by MRI. Panel
a is a representative image of a WT mouse with normal prostate
(highlighted in blue). Panel b is a representative MR image of PCA in an
iBRAF* male on doxycycline (red outline; note heterogeneous signals
within the lesion). Panel c is a representative MR image of
hydronephrosis detected in an iBRAF* mouse with PCA. Note enlarged
distended kidney (yellow arrow) in contrast to normal kidney in panel b
(green arrow), indicating accumulation of urine in the kidney due to
outflow obstruction by the tumor.
doi:10.1371/journal.pone.0003949.g002
Figure 3. iBRAF* prostate tumors exhibit epithelial lineage
markers. Both ductal and spindled components of iBRAF* prostate
tumors express epithelial lineage markers: CK14 and p63 for basal cell,
AR and Nkx3.1 for luminal cell, and CK19 for transit-amplifying cells.
doi:10.1371/journal.pone.0003949.g003
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was observed in these tissue recombinant specimens similar to
tumors from de novo transgenic mice (Figure 5C right panel and data
not shown for p-ERK). In summary, lineage marker characteriza-
tion of de novo transgenic tumors, coupled with the functional data in
the tissue recombinant system, provides clear evidence that iBRAF*
PCA are invasive adenocarcinomas expressing luminal, intermedi-
ate and basal cell markers.
iBRAF* PCA progress to indolent androgen-independent
tumors after castration
Emergence of androgen-independence represents the most
significant disease process in human PCA from the standpoint of
mortality, prompting us to determine whether the iBRAF* model
develops androgen independent (AI) tumors. To this end, we
identified 10 iBRAF* mice with documented PCA by MRI
screening for heterogeneous mass in the prostate gland (repre-
Figure 4. iBRAF* embryonic urogenital epithelium drives basaloid hyperplasia in the tissue recombination system. A. Schematic
representation of the tissue recombination protocol. Recombinants of iBRAF* transgenic mouse epithelium and rat mesenchyme (Recomb A) were
grafted under the right kidney capsules of adult nude mice. The converse recombinants (iBRAF* transgenic mouse mesenchyme and rat epithelium;
Recomb B) were also transplanted in the same manner into the left kidney capsule of the same mice. Three of the grafted mice were fed doxycycline
drinking water, and two were not. As controls, recombinants of non-transgenic wild-type mouse epithelium and rat mesenchyme (Recomb C) and the
converse recombinants (Recomb D) were grafted in the same manner. Grafts were harvested 6 weeks later. B. Macroscopic images show that grafts
with Recomb A on doxycycline are larger than both grafts with Recomb B on doxycycline and grafts with Recomb A off doxycycline. C. Histological
analysis of these tissue grafts confirmed basaloid hyperplasia only in grafts with Recomb A on doxycycline, while others showed normal histology.
doi:10.1371/journal.pone.0003949.g004
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an effort to relieve outlet obstruction, 50% (n=5) animals
succumbed peri-operatively which was likely due to a generally
compromised physiological state secondary to renal failure. Of the
surviving animals, two were sacrificed at one-week post-castration
(#36 and #57) and the remaining 3 were followed by weekly MRI
for 4 weeks. Volumes of the prostate mass in all 5 mice decreased
during the observation period (Figure 6A and Supporting Figure
S4) but histopathological examination identified residual tumor
nodules in two of the five castrated iBRAF* mice (#46 and #57).
These tumor nodules were AR+ and p63+ with strong p-ERK and
p-S6K activation but without detectable p-AKT (Figure 6B). That
they were comprised of viable malignant cells was shown by low
apoptosis index, comparable with index observed in pre-castrated
tumor (Figure 6C). However, compared to the rapidly growing
pre-castration tumors, these post-castrated tumors were indolent,
with proliferation indices of 6.8 (+/23.6) and 6.2 (+/22.2),
respectively, compared to an index of 26.6 (+/23.6) in the pre-
castrated tumors (n=300 nuclei/area65 areas counted in each
sample; p,0.001 for both; Figure 6C). Thus, it appears that BRAF
driven ERK and S6K activation alone is not sufficient to drive
androgen-independent growth post castration, although it appears
to be permissive of survival in low androgen state.
BRAF activation is not required for iBRAF* PCA
maintenance
To determine whether constitutive BRAF* signaling is required
for iBRAF* tumor maintenance, we performed doxycycline
withdrawal study in iBRAF* transgenic animals with documented
PCA by MRI or by physical examination. First, two iBRAF* mice
were identified as tumor-bearing and enlisted into serial MRI after
doxycycline was removed from the drinking water. Unexpectedly,
tumors continued to grow in both animals as shown on MRI
(Figure 7A), requiring termination and sacrifice of ZD839 at one
week and ZD835 at 4 weeks post doxycycline withdrawal.
Similarly, two additional iBRAF* mice with tumors by palpation
were taken off doxycycline; close follow-up revealed continued
tumor growth, requiring sacrifice at 2 weeks and 4 weeks,
Figure 5. iBRAF* prostate tumors are AKT-independent. A, B. p-ERK activation in iBRAF* PCA tumors (n=5; on doxycycline) was detected by
immunoblotting analysis (A) and IHC (B). In contrast, p-AKT activation was not detected in all iBRAF* PCA tumors (n=5; on doxycycline). Controls (a &
b) were two prostate cancer samples from Pten-null mice and WT was prostate glands from a WT mouse. C. p-AKT immunoreactivity was not
detected on iBRAF* PCA tumors (n=17) and Recomb A (a recombinant of iBRAF* transgenic mouse epithelium and rat mesenchyme on doxycycline)
by IHC, but strong immunoreactivity of p-S6 was still present. PCA sample from Nkx3.12/2, Pten+/2 compound mutant mice were used as control.
doi:10.1371/journal.pone.0003949.g005
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not express BRAF* by Western blot analysis (Figure 7B) or by IHC
(Figure 7C, compare immunoreactivity to left panel). Accordingly,
ERK phosphorylation was undetectable in ZD839 and only patchy
in ZD835. Consistent with its continued growth in vivo, robust Ki67
and minimal TUNEL staining was documented in these off-
doxycycline tumors, similar to the profile of on-doxycycline iBRAF*
PCA. Taken together, these observations indicate that, while
sustained BRAF* activation in the prostate gland is sufficient to
drive development of invasive prostate adenocarcinoma, it is not
required for maintenance of established PCA.
Discussion
This study, together with recently reported BRAF mutations in
human prostate tumors[25], demonstrates the pathogenetic
relevance of MAP kinase activation in prostate tumorigenesis. By
targeting BRAF V600E–a human-relevant mutation known to
potently activate MAP kinase–to the mouse prostate epithelium,
we show here that MAP kinase activation can drive aberration
proliferation and basaloid hyperplasia, leading to emergence of
invasive adenocarcinoma of the prostate gland with short latency
and high penetrance without evidence of AKT activation. The
profile of strong ERK and S6K activation in the absence of AKT
in iBRAF* tumors is consistent with the model proposed by
Pandolfi and colleagues, whereby constitutive ERK activation
inhibits TSC complex and subsequent activation of mTOR and
downstream S6K[42]. In a cohort of four BRAF
V600E mutated
human PCA with strong pERK and pS6K activation by IHC,
weak to absent pAKT immunoreactivity was indeed observed in
two (#S04-7014 and #S04-7989 in Supporting Figure S6),
supporting the notion that this iBRAF* transgenic system is
modeling a subset of human PCA.
In mouse and human systems, activation of both AKT and
ERK signaling is commonly observed during the initiation and
progression of PCA[26,43]. Since most mouse prostate cancer
models are driven by AKT-activation, independent contribution
of MAPK activation to prostate tumorigenesis has been difficult to
establish. Here, by demonstrating that evolution from benign
hyperplasia to invasive prostate tumors without concomitant AKT
activation, this iBRAF* model offers the first genetic proof that
MAPK activation alone is sufficient for initiation and progression
Figure 6. iBRAF* PCA progress to indolent androgen-independence after castration. A. The reduction of tumor volumes was monitored
by MRI over a 4-week time course after castration (a, tumor (blue) 1 week after castration; b, tumor (green) 2 weeks after castration; c, tumor (yellow)
3 weeks after castration; d, tumor (orange) 4 weeks after castration). Asterisk indicates bladder. B. Histological examination confirmed the presence
of prostatic tumor cells in two castrated iBRAF* mice (#46 and #57). The two post-castration tumors were positive for AR (a prostatic luminal cell
marker) and p63 (a basal cell marker) by IHC. Also, the post-castration tumor cells were negative for p-AKT, but remained strongly positive for p-ERK
and p-S6K on IHC. C. The post-castration tumor cells were viable and growing, not residual tumor remnants, as manifested by low apoptosis index
(1.2 (+/20.45) and 1.4 (+/20.55) per 100 nuclei for #46 and #57, respectively) on TUNEL, comparable to pre-castration tumor (1.0 (+/20.71)) (top),
and active proliferation by Ki67 staining, albeit at rate much lower than that of pre-castration tumor (6.8 (+/23.6) and 6.2 (+/22.2) for #46 and #57,
respectively and 26.6 (+/23.6) in the pre-castrated tumors) (bottom).
doi:10.1371/journal.pone.0003949.g006
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activation via mutant BRAF expression under an androgen-
insensitive promoter renders this iBRAF* model an ideal system for
genetic dissection of MAPK contribution independent of AKT
during AI progression. In this regard, although they grow rapidly
in androgen-rich conditions, these AKT-negative iBRAF* PCA
undergo complete or significant regression upon castration. Those
indolent lesions surviving castration remain pAKT negative,
pointing to its dispensability for survival in low-androgen state
but likely requirement for AI growth in vivo, in line with recent
study in ex-vivo manipulated system[26]. In summary, we conclude
that while it may be permissive for survival post castration, BRAF
driven MAPK activation is not sufficient to drive active growth
under an androgen-limited state.
Figure 7. iBRAF* prostate tumors do not require BRAF activation for their tumor maintenance. A. Tumor size change was monitored by
serial MRI imaging before (baseline; solid line) and after (indicated periods; dotted line) doxycycline withdrawal (7 days for ZD839 and 28 days for
ZD835). Yellow line indicates tumor boundary. B. B-RAF expression and p-ERK activation were not detected by immunoblotting analysis in most of off
doxycycline iBRAF* PCA tumors (n=3), although one of the off doxycycline iBRAF* tumor samples (ZD835) showed weak p-ERK activation. C.
Immunohistological examination using antibodies against B-RAF and p-ERK confirmed the repression of B-RAF* transgene repression during off
doxycycline periods (7 days for ZD839 and 28 days for ZD835). However, the tumors were viable and still growing, as manifested by low apoptosis on
TUNEL and active proliferation by Ki67 staining.
doi:10.1371/journal.pone.0003949.g007
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tumorigenesis, continued mutant BRAF expression or downstream
MAPK activation is not required for maintenance of established
PCA. Genetic inactivation of BRAF* by doxycycline withdrawal
in 4 BRAF*-driven tumors did not lead to tumor growth inhibition
nor regression. Corroborating with this was an intriguing finding
that pharmacological inhibition of MEK with CI-1040 in renal
capsule grafts of iBRAF* tumors (n=2) did not inhibit tumor
growth despite extinction of pERK activities (Supporting Figure
S5). Taken together, these observations indicate that continued
expression of mutant BRAF or activation of MAPK is not required
to sustain growth or maintain viability of established PCA. This
contrasts with findings in BRAF*-driven lung adenocarcinoma
model where BRAF* acts not only as an initiating oncogene but
shown to be required for maintenance[44], highlighting the
context/lineage specific role(s) of an oncogenic event in genesis,
progression and maintenance.
In summary, we describe here a novel genetically engineered
mouse model of invasive PCA driven by MAPK activation via
inducible BRAF mutation under an androgen-insensitive promot-
er. This model serves as a unique system for dissecting
contribution of MAPK, relative to AKT, in development,
progression and treatment of PCA.
Materials and Methods
Generation of inducible BRAF* (iBRAF*) transgenic mice
A human wild-type BRAF cDNA was cloned into a pBKS
plasmid with its expression under the control of a minimal
promoter containing multimerized tet-operons. A constitutively
active form of mutant BRAF
E600 was generated from the pBSK
plasmid using QuikChangeH Site-Directed Mutagenesis Kit
(Stratagene) (designated Tet-BRAF
*). The Tet-BRAF
* construct
was injected into oocytes derived from Ink4a/Arf null mice.
Transgenic mouse lines harboring the Tet- BRAF
* elements were
crossed with another transgenic mouse lines expressing the reverse
tetracycline transactivator under the control of the tyrosinase
promoter/enhancer elements (designated Tyr-rtTA) to produce
cohorts of single (Tet-BRAF*) and double (designated iBRAF*,
Tet-BRAF*; Tyr-rtTA) transgenic animals. Doxycycline-supple-
mental drinking water was administered to induce transgene
BRAF
E600 expression as previously described[35].
All animal experiments were performed according to a protocol
approved by the Institutional Animal Care and Use Committee
(IACUC) at Harvard Medical School.
Transplantation of tissue recombinants
A two-way tissue recombination was performed. Mouse and rat
embryonic urogenital sinuses were obtained at 16.5 days post
coitum (dpc) and 18.5 dpc, respectively, as described previous-
ly[41]. After treatment of trypsin, epithelium and mesenchyme
were separated under the microscope. Next, mouse urogenital
sinus epithelium (mUGE) and rat urogenital sinus mesenchyme
(rUGM), or mouse urogenital sinus mesenchyme (mUGM) and rat
urogenital sinus epithelium (rUGE), were combined. Tissue
recombinants were grafted under the kidney capsules of adult
male nude mouse host for 6 weeks (with doxycycline on or off).
Upon harvesting the grafts, tissues were fixed in 10% formalin
overnight, and processed for histology and immunostaining.
Histology and immunohistochemistry
All the tissue samples were fixed in 10% formalin overnight and
embedded in paraffin. Immunohistochemistry were performed as
described previously[45]. For antigen retrieval, slides were heated
in 0.01 M citrate buffer (pH 6.0) in the microwave four times at
four minutes each time. The antibodies and dilutions are: BRAF,
1:250 (Santa Cruz); phospho-Erk, 1:250 (Cell Signaling); Andro-
gen Receptor, 1:250 (ABR); Ki-67, 1:2000 (Novacastra); Cytoker-
atin-14, 1: 50 (Biogenex); p63, 1:600 (Santa Cruz); Chromogranin
A, 1:4000 (Diasorin); Synaptophysin, 1:500 (Santa Cruz);
phospho-p70 S6 kinase 1:250 (Cell Signaling); E-cadherin, 1:250
(transduction lab); phospho-AKT(Ser473), 1:100 (Cell Signaling);
Nkx3.1, 1:6000 (kindly provided by Dr. Cory Abate-Shen); and
Cytokeratin 19, 1:20 (kindly provided by Dr. Nabeel Bardeesy).
Apoptotic cell death was detected using the ApopTagH Plus
Peroxidase In Situ Apoptosis Detection Kit (Chemicon).
RNA In-situ hybridization (RISH)
The 10% formalin-fixed, paraffin-embedded slides were used for
in situ hybridization with DIG-labeled riboprobe. DIG-labeled
RNA probes were synthesized from a pBKS plasmid containing a
rtTA PCR product (500 bp) using either T7 (for sense probe) or T3
(for anti-sense probe) promoter by in vitro transcription system with
DIG RNA Labeling Mix (Roche Molecular Biochemicals, Man-
nheim, Germany). After deparaffinization, slides were digested in
proteinase K solution (50 ug/ml) for 10 minutes at 37uC. DIG-
labeled rtTA RNA probes were diluted in hybridization buffer at
the concentration of 1 ug/ml. 100 ul of the diluted RNA probes
was added on each slide and covered by 24640 mm
2 coverslip.
Slides were hybridized at 60uC overnight, and washed at 65uC for
15 minutes twice in 26SSC buffer with gentle agitating. After the
treatment of RNAse A (10 ug/ml) for 30 minutes at 37uC, the slides
were washed for 10 minutes twice at room temperature (RT) in 26
SSCbufferandfollowed byadditional washingfor30 minutestwice
at 65uC in 0.26SSC buffer with gentle agitation. The slides were
washed in PBS for 15 minutes twice at RT and then incubated with
anti-Digoxigenin antibody conjugated with alkaline phosphatase
(1:2000, Roche) overnight at 4uC. Color was developed by dipping
the slides in NTB/BCIP solution[46,47] approximately for two to
four hours in the dark.
For the dual staining, first with immunohistochemical staining
procedure, the quick incubation of the slides with antibody against
p63 for 10 minutes was performed, and then followed by RNA in
situ hybridization procedure with rtTA RNA probe as mentioned
above.
MRI methods
Magnetic resonance imaging was performed on a 4.7 T on a
Bruker imaging system (Pharmascan, Karlsruhe, Germany). Proto-
cols included a Tri-plane and coronal proton density weighted
localizer. Multi-slice T2-weighted imaging was performed in the
coronal and axial planes utilizing the following parameters: Flip
angle=90u; Matrix size (2566256); TR=2500 msec; TE=
44.6 ms; field of view (FOV)=4.2462.12 cm, slice thick-
ness=1.2 mm. T1-weighted imaging was performed in the coronal
and axial planes following the administration of intraperitoneal Gd-
DTPA utilizing the following parameters: Flip angle=90u;M a t r i x
size (2566256); TR=700 msec.; TE=14 msec.; field of view
(FOV)=4.2462.12 cm, slice thickness=1.2 mm. Tumor volumes
were determined by region of interest (ROI) analysis of T1-weighted
post Gd-DTPA enhanced images using robust image analysis
software (OsirixH). The sum of the region of interests was multiplied
by the slice thickness to obtain tumor volumes. Tumor volumes are
reported in cubic centimeter (cc).
Molecular analysis
RNA was isolated from the prostate tumor samples, and
reverse-transcribed to cDNA as described previously[45]. A RT-
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expression was as follows (210-bp fragment):
RTM-BRAF-5F: 59-TCTTCATGAAGACCTCACA-39
RTM-BRAF-5R: 59-ACTGTCCAGTCATCAATTCA-39
PCR amplification condition was 95uC for 15 min followed by
95uC for 1 min, 62uC for 1 min, and 72uC for 1 min with 31
cycles. As an internal control for RT-PCR, ribosomal protein R15
expression was used.
For western blot analysis, tumor lysates were extracted as
described previously[45]. Total 20 micrograms of lysate was run
on 4–12% Bis-Tris NuPAGE (Invitrogen), transferred to PVDF
membrane (Perkinelmer), and blotted using the following
antibodies: p-ERK, 1:500 (Cell Signaling); phospho-S6 Kinase,
1:500 (Cell Signaling); and p-AKT(Ser473), 1:250 (Cell Signaling).
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0003949.s001 (0.03 MBRTF)
Figure S1 BRAF* transgene expression is documented by
transgene-specific RT-PCR with two independent prostate tumors
of bi-transgenic iBRAF* mice on doxycycline.
Found at: doi:10.1371/journal.pone.0003949.s002 (1.37 MB TIF)
Figure S2 Both ductal and spindled components of iBRAF*
prostate tumors were negative for neuroendocrine markers
(chromogranin and synaptophysin) by IHC. For controls,
pancreatic tissues were used.
Found at: doi:10.1371/journal.pone.0003949.s003 (1.37 MB TIF)
Figure S3 Grafts from recombinant study showed a profile of
lineage marker that is identical to that of the de novo iBRAF* PCA
tumors.
Found at: doi:10.1371/journal.pone.0003949.s004 (1.37 MB TIF)
Figure S4 iBRAF* tumors regress after castration. A. Repre-
sentative consecutive multi-slice MRI images (1.2 mm thickness) of
pelvis of iBRAF* mouse #46 at baseline imaging (pre-castration)
showing heterogeneous signal intensity characteristic of tumor
(blue highlight). B. Changes in prostate tumor volumes over time
after castration (n=5) were calculated based on ROI on serial
MRI images. For comparison, serial imaging of a WT mouse was
shown. Asterisks indicate two post-castration tumors containing
prostatic tumor cells on histological examination.
Found at: doi:10.1371/journal.pone.0003949.s005 (1.37 MB TIF)
Figure S5 Activation of B-RAF pathway is not required for
tumor progression and maintenance. A. Schematic representation
of CI-1040 (a MEK inhibitor) treatment protocol using tissue
recombination. Tissue recombinants were generated with iBRAF*
prostate cancer cells and rat mesenchymal cells, implanted under
the kidney capsule of nude mice, and grown for 2 months. The
mice were orally treated with CI-1040 at 150 mg/kg body weight
twice a day for two weeks. B. Gross morphology and graft weight
after two-week treatment showed significantly increased graft size
with CI-1040 treatment, compared to mock-treated control
(p=0.032). C. Histological analyses of grafts from mock-treated
and CI-1040-treated mice confirmed prostate tumor development.
Although decreased p-ERK staining with CI-1040-treated mice
indicated the inhibition of B-RAF pathway, tumors were still
proliferating, as manifested by strong positivity with Ki67 staining.
Found at: doi:10.1371/journal.pone.0003949.s006 (1.37 MB TIF)
Figure S6 Strong activation of p-ERK and p-S6K was also
observed in human prostate tumors harboring BRAFV600E
mutation (total 8 samples; n=4 with WT BRAF and n=4 with
BRAFV600E mutation). Importantly, two of the four human
prostate tumors harboring BRAFV600E mutation showed no
activation (BRAF V600 #S04-7014) or very weak activation of p-
AKT (BRAF V600 #S04-7989).
Found at: doi:10.1371/journal.pone.0003949.s007 (1.37 MB TIF)
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